<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002892</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065215</org_study_id>
    <secondary_id>NCRI-AIM-HIGH</secondary_id>
    <secondary_id>EU-96052</secondary_id>
    <secondary_id>UKCCCR-AIM-HIGH</secondary_id>
    <nct_id>NCT00002892</nct_id>
  </id_info>
  <brief_title>Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma</brief_title>
  <official_title>A RANDOMISED STUDY OF OBSERVATION VERSUS ADJUVANT LOW DOSE EXTENDED DURATION INTERFERON ALPHA-2A IN COMPLETELY RESECTED HIGH RISK MALIGNANT MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet&#xD;
      known whether interferon alfa following surgery is more effective than surgery alone in&#xD;
      treating patients with melanoma.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with no&#xD;
      further therapy following surgery in treating patients with stage II, stage III, or recurrent&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the effects of adjuvant low-dose extended-duration interferon alfa&#xD;
      on disease-free and overall survival in patients with completely resected malignant melanoma&#xD;
      at high risk of recurrence. II. Determine any correlation between patient age or sex and the&#xD;
      effects of interferon therapy on disease-free and overall survival. III. Describe the toxic&#xD;
      effects of this treatment. IV. Evaluate the economic implications of implementing effective&#xD;
      interferon therapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients will be stratified by age, sex, disease status&#xD;
      at entry, and participating institution. Patients are randomized to observation only or to&#xD;
      receive interferon alfa by subcutaneous injections 3 times weekly for 2 years, or until&#xD;
      disease progression or toxicity intervenes. Patients are followed monthly for 6 months,&#xD;
      quarterly for 18 months, and every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 1,000 patients will be entered over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1995</start_date>
  <completion_date type="Actual">December 2001</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed malignant melanoma definitively resected&#xD;
        within 12 weeks prior to entry One of the following categories: Stage II disease (greater&#xD;
        than 4 mm Breslow thickness) Stage III disease (regional lymph node involvement) Recurrent&#xD;
        non-nodal superficial regional disease (local or in transit) Recurrent regional nodal&#xD;
        involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Able to tolerate interferon No second malignancy except curatively&#xD;
        treated: Carcinoma of the cervix Nonmelanomatous skin cancer No pregnant or nursing women&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: No prior immunosuppressive therapy, including systemic steroids&#xD;
        No prior biologic therapy Recovered from surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry W. Hancock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Centre at Weston Park Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead, London</city>
        <state>England</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's, King's and St. Thomas' Hospitals Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital N.H.S. Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology NHS Trust</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>L63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selly Oak Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B29 6JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>King's Lynn</city>
        <zip>PE30 4ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salisbury District Hospital</name>
      <address>
        <city>Salisbury</city>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend Hospital</name>
      <address>
        <city>Southend on Sea</city>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004 Jan 1;22(1):53-61. doi: 10.1200/JCO.2004.03.185. Epub 2003 Dec 9.</citation>
    <PMID>14665609</PMID>
  </results_reference>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 12, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

